[ad_1]
San Francisco, December 18, 2021 (Global News Agency)-Hagens Berman urges Revance Therapeutics, Inc. (Nasdaq:RVNC) Investors suffered heavy losses Submit your loss immediately.
| class time: November 25, 2019 – October 11, 2021 | |
| Deadline for lead plaintiff: February 8, 2022 | |
| access: www.hbsslaw.com/investor-fraud/RVNC | |
| Contact a lawyer immediately: | RVNC@hbsslaw.com |
| 844-916-0895 | |
Revance Therapeutics, Inc. (RVNC) Securities Class Action:
The complaint alleges that the defendant misrepresented and omitted important facts related to the manufacturing and regulatory approval of Revance’s main product drug candidate DAXI for the treatment of frown lines.
Specifically, the defendant concealed: (i) The company’s manufacturing plant for DAXI had quality control defects; (ii) the above…
The full story can be found on Benzinga.com
[ad_2]
Source link
